نتایج جستجو برای: recombinant tissue plasminogen activator

تعداد نتایج: 1042779  

Journal: :Stroke 2010
Xiang Fan Zhanyang Yu Jianxiang Liu Ning Liu Katherine A Hajjar Karen L Furie Eng H Lo Xiaoying Wang

Hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and the short treatment time window comprise major challenges for thrombolytic therapy. Improving tissue plasminogen activator therapy has become one of the highest priorities in the stroke field. Recent efforts have been aimed at identifying new strategies that might enhance the thrombolytic efficacy of tissue plasminogen activ...

Journal: :journal of current ophthalmology 0
محمدصادق فره وش mohammad-sadegh farahvash مسعود اقصائی فرد masood aghsaie-fard احمد میرشاهی ahmad mirshahi علیرضا لاشیئی alireza lashay احمد جوادیان ahmad javadian هوشنگ فقیهی hooshang faghihi مرضیه مرادی مقدم

purpose: to compare the effect of tissue plasminogen activator (tpa) and aspirin in patients with central retinal vein occlusion. methods: a prospective interventional study was conducted on patients with central retinal vein occlusion of less than 28 days' duration. patients in the tpa group received 100 μg intravitreal tissue plasminogen activator and the patients who declined intravitre...

Journal: :The Journal of clinical investigation 1986
A Ichinose K Takio K Fujikawa

Functionally active A and B chains were separated from a two-chain form of recombinant tissue-type plasminogen activator after mild reduction and alkylation. The A chain was found to be responsible for the binding to lysine-Sepharose or fibrin and the B chain contained the catalytic activity of tissue-type plasminogen activator. An extensive reduction of two-chain tissue-type plasminogen activa...

Journal: :Stroke 2012
Masatoshi Koga Yoshiaki Shiokawa Jyoji Nakagawara Eisuke Furui Kazumi Kimura Hiroshi Yamagami Yasushi Okada Yasuhiro Hasegawa Kazuomi Kario Satoshi Okuda Kaoru Endo Tetsuya Miyagi Masato Osaki Kazuo Minematsu Kazunori Toyoda

BACKGROUND AND PURPOSE The purpose of this study was to determine the safety and efficacy of intravenous recombinant tissue-type plasminogen activator (0.6 mg/kg alteplase) within 3 hours of stroke onset in Japanese patients outside the indications in the European license. METHODS Of the 600 patients who were treated with recombinant tissue-type plasminogen activator, 422 met the inclusion cr...

Journal: :Stroke 2011
Daniel B Herrick Wendy C Ziai Carol B Thompson Karen Lane Nichol A McBee Daniel F Hanley

BACKGROUND AND PURPOSE This is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH). METHODS Laboratory data from subjects enrolled onto the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We ...

Journal: :Stroke 2010
Kathryn E Hitchcock Christy K Holland

BACKGROUND AND PURPOSE Ultrasound has been shown to increase recombinant tissue plasminogen activator thrombolysis through stable cavitation, or sustained bubble activity, but this mechanism needs further optimization. Use of low-frequency ultrasound in combination with microbubbles stabilized against dissolution, in the form of ultrasound contrast agents, has resulted in greater lytic efficacy...

Journal: :Stroke 2008
Joan Martí-Fàbregas Montserrat Borrell Dolores Cocho Sergi Martínez-Ramírez Mercè Martínez-Corral Jordi Fontcuberta Josep-Lluis Martí-Vilalta

BACKGROUND AND PURPOSE We evaluated the association between recombinant tissue-type plasminogen activator recanalization and change in hemostatic markers. METHODS We studied 40 patients. Recanalization was measured with transcranial Doppler. We evaluated the change in markers of coagulation (fibrinogen) and fibrinolysis (thrombin activatable fibrinolysis inhibitor and alpha(2)-antiplasmin) in...

Journal: :modares journal of medical sciences: pathobiology 2013
azam rahimpour behrouz vaziri farzaneh barkhordari leila nematollahi ahmad adeli

objective: development of high producing mammalian cell lines is a major bottleneck in manufacturing of recombinant therapeutic proteins. this study examines the effect of using the matrix attachment region from the human interferon beta gene in combination with promoter activation strategy with e1a 13s protein on human tissue plasminogen activator (t-pa) expression in chinese hamster ovary (ch...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید